Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
04 Aug 2023
04 Aug 2023
Historique:
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
6
8
2023
Statut:
ppublish
Résumé
Ranibizumab addition may benefit to improve the efficacy in patients with diabetic retinopathy than only photocoagulation, and this meta-analysis aims to explore the impact of ranibizumab addition on efficacy for diabetic retinopathy. PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis. Six randomized controlled trials were finally included in the meta-analysis. Overall, compared with control intervention for diabetic retinopathy, ranibizumab addition showed significantly increased number of neovascularization area reduction (OR = 4.20; 95% CI = 1.47-12.02; P = .007) and reduced fluorescein leakage (MD = -2.53; 95% CI = -3.31 to -1.75; P < .00001), but showed no obvious impact on neovascularization area (MD = -1.80; 95% CI = -3.68 to 0.08; P = .06), photocoagulation retreatment (OR = 1.03; 95% CI = 0.47-2.27; P = .94) or adverse events (OR = 1.45; 95% CI = 0.49-4.29; P = .50). Ranibizumab combined with photocoagulation is effective to improve efficacy for diabetic retinopathy.
Sections du résumé
BACKGROUND
BACKGROUND
Ranibizumab addition may benefit to improve the efficacy in patients with diabetic retinopathy than only photocoagulation, and this meta-analysis aims to explore the impact of ranibizumab addition on efficacy for diabetic retinopathy.
METHODS
METHODS
PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis.
RESULTS
RESULTS
Six randomized controlled trials were finally included in the meta-analysis. Overall, compared with control intervention for diabetic retinopathy, ranibizumab addition showed significantly increased number of neovascularization area reduction (OR = 4.20; 95% CI = 1.47-12.02; P = .007) and reduced fluorescein leakage (MD = -2.53; 95% CI = -3.31 to -1.75; P < .00001), but showed no obvious impact on neovascularization area (MD = -1.80; 95% CI = -3.68 to 0.08; P = .06), photocoagulation retreatment (OR = 1.03; 95% CI = 0.47-2.27; P = .94) or adverse events (OR = 1.45; 95% CI = 0.49-4.29; P = .50).
CONCLUSIONS
CONCLUSIONS
Ranibizumab combined with photocoagulation is effective to improve efficacy for diabetic retinopathy.
Identifiants
pubmed: 37543834
doi: 10.1097/MD.0000000000034170
pii: 00005792-202308040-00077
pmc: PMC10403042
doi:
Substances chimiques
Ranibizumab
ZL1R02VT79
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Vascular Endothelial Growth Factor A
0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34170Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Ophthalmol Retina. 2021 Feb;5(2):151-159
pubmed: 32693033
Eye (Lond). 2009 Jan;23(1):117-23
pubmed: 17891058
Am J Pathol. 2012 Aug;181(2):376-9
pubmed: 22749677
Retin Cases Brief Rep. 2017 Spring;11(2):114-118
pubmed: 27100568
JAMA. 2020 Dec 15;324(23):2383-2395
pubmed: 33320223
Beyoglu Eye J. 2021 Feb 10;6(1):49-53
pubmed: 35005492
Diabet Med. 2019 Apr;36(4):424-433
pubmed: 30474144
Ophthalmologica. 2016;235(1):34-41
pubmed: 26630400
Acta Ophthalmol. 2020 Aug;98(5):e530-e539
pubmed: 31808278
Am J Ophthalmol. 1976 Apr;81(4):383-96
pubmed: 944535
Ann Intern Med. 2001 Dec 4;135(11):982-9
pubmed: 11730399
Am J Ophthalmol. 1994 Oct 15;118(4):445-50
pubmed: 7943121
Doc Ophthalmol. 2012 Jun;124(3):225-36
pubmed: 22457045
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Eur J Ophthalmol. 2020 Jan;30(1):34-39
pubmed: 30539668
Curr Diab Rep. 2021 Nov 1;21(10):43
pubmed: 34719742
Retina. 2015 Feb;35(2):280-7
pubmed: 25272318
JAMA. 2015 Nov 24;314(20):2137-2146
pubmed: 26565927
Ophthalmic Res. 2019;62(4):225-230
pubmed: 31554001
Acta Ophthalmol. 2011 Nov;89(7):e567-72
pubmed: 21726427
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32797181
Lancet Diabetes Endocrinol. 2019 Feb;7(2):140-149
pubmed: 30005958
Ophthalmology. 2006 Jan;113(1):23-8
pubmed: 16343627
Ther Clin Risk Manag. 2016 Apr 05;12:527-33
pubmed: 27103811
BMC Ophthalmol. 2021 Mar 9;21(1):129
pubmed: 33750339
Curr Diab Rep. 2021 Sep 3;21(9):33
pubmed: 34477996
BMJ Case Rep. 2021 Feb 4;14(2):
pubmed: 33541966
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Ophthalmology. 2018 May;125(5):691-700
pubmed: 29395119
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148
pubmed: 30043039
Lancet. 2017 Jun 3;389(10085):2193-2203
pubmed: 28494920
Am J Ophthalmol. 2019 Nov;207:279-287
pubmed: 31095954
N Engl J Med. 1994 Dec 1;331(22):1480-7
pubmed: 7526212